The advisory committee meeting introduces binary risk — watch for the meeting date announcement and any FDA briefing documents for signal on panel sentiment. The Q1 2027 PDUFA is the next hard catalyst.
Price Chart
Executive Summary
Biohaven announced that the FDA accepted for review its resubmitted NDA for troriluzole (Vyglxia) in spinocerebellar ataxia (SCA), with a PDUFA goal date in Q1 2027. The FDA plans to convene an advisory committee meeting, introducing binary approval risk. This is a regulatory milestone for a drug previously rejected, with no financial data or guidance provided.
Key Facts
- FDA accepted Biohaven's NDA resubmission for troriluzole (Vyglxia) in spinocerebellar ataxia (SCA) for review.
- The resubmission is considered a complete response to the November 4, 2025 complete response letter.
- PDUFA goal date assigned in Q1 2027.
- FDA plans to convene a Peripheral and Central Nervous System Advisory Committee meeting; date forthcoming.
- Troriluzole is investigational and not yet approved for any indication in the US.
Financial Impact
No financial figures provided; SCA is an orphan indication with significant unmet need, representing a potential multi-hundred-million to billion-dollar peak sales opportunity if approved.
Risk Factors
- Advisory committee could vote against approval, as seen in prior SCA drug reviews.
- FDA may extend review or issue another complete response letter.
- No revenue or earnings data in filing to assess financial health.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001935979-26-000083 |
| Document: 0001935979-26-000083-index-headers.html | 0001935979-26-000083 |
| Document: 0001935979-26-000083-index.html | 0001935979-26-000083 |
| Document: 0001935979-26-000083.txt | 0001935979-26-000083 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $14.69 | awaiting T+5 | — | $13.88 (−5.51%) |
Oct 15, 2026 10d ago | 8-K | $10.78 $13.88 | ▲ +28.76% | ▲ +29.19% | $13.88 (+28.76%) |
Sep 9, 2026 6w ago | 8-K | $12.79 $13.89 | ▼ −8.60% | ▼ −9.10% | $13.88 (−8.52%) |
Aug 26, 2026 8w ago | 8-K | $16.95 $15.69 | ▼ −7.43% | ▼ −7.31% | $13.88 (−18.11%) |
Aug 10, 2026 10w ago | 8-K | $14.49 $13.57 | ▼ −6.35% | ▼ −5.95% | $13.88 (−4.21%) |
Jul 9, 2026 15w ago | 8-K | $15.55 $14.17 | ▼ −8.87% | ▼ −8.31% | $13.88 (−10.74%) |
May 27, 2026 21w ago | 8-K | $10.24 $11.40 | ▲ +11.33% | ▲ +11.01% | $13.88 (+35.55%) |
May 4, 2026 24w ago | 424B5 | $9.71 $9.20 | ▲ +5.25% | ▲ +7.24% | $13.88 (−42.95%) |
May 4, 2026 24w ago | S-3ASR | $9.71 $9.20 | ▼ −5.25% | ▼ −7.24% | $13.88 (+42.95%) |
May 4, 2026 24w ago | 8-K | $9.71 $9.20 | ▼ −5.25% | ▼ −7.24% | $13.88 (+42.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers